aless12 Posted - 1 week ago

$ADCT Anybody drug conjugate are the future $DSNKY $BMY

aless12 Posted - 1 week ago

$DSNKY $ADCT probably fusion ?

NewMexicats Posted - 10/31/24

$BVAXF $DSNKY

YoloAlfred Posted - 10/29/24

$DSNKY $ESPR & $DSNKY

YoloAlfred Posted - 10/25/24

$DSNKY

SparkyReturns Posted - 10/24/24

$XERS Ok, I'll admit that I was wrong. I did not expect this much strength. I thought it was going to bounce around $3.00 much longer than it has so far. I have to think that some shorts are starting to cover, or maybe the news is starting to get out about how undervalued this is due to XP-8121 going into Ph III soon and the big pharma collaborations which have the potential for scalability and big milestones and royalties. Cheers! $DSNKY $PFE $MRK $MRNA

YoloAlfred Posted - 1 month ago

$DSNKY 🤫🤫🤫🤫

PenkeTrading Posted - 09/24/24

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Daiichi Sankyo Co Ltd ADR. Is that bullish or bearish? $DSNKY #RsiOversold #PINK

aless12 Posted - 2 months ago

$DSNKY Pay attention to $ADCT

SparkyReturns Posted - 3 months ago

$TAK Check out XERS for another biotech investing idea. Their high-concentration Sub-Q delivery tech can be used with MANY drugs currently being delivered by IV by your company, especially MAbs. XERS already has collabs with big pharma REGN, AMGN, and Beta Bionics. AMGN even ditched HALO recently to go with XERS delivery system instead for Tepezza because higher concentrations and no need for refrigeration. Why am I so optimistic? 1. Stable and growing revenue base of 3 products. 2. SubQ Levo (XP-8121 thyroid treatment) will solve administration issues for people with gastro issues/pills, $2-3B TAM. XERS has hinted about bringing on a partner to monetize value. 3. Will hear soon on collabs with Amgen, Regeneron, and Beta Bionics and will learn soon what the terms are of their upfront payments and milestone payments. 4. Tutes have been quietly loading up, highest institutional ownership ever. How do you like the chart?! Cheers! $DSNKY $ILMN $ALXN $SGEN

Rustyton Posted - 3 months ago

$ESPR Meanwhile, $DSNKY has gone from $30 to $40 in recent months

PenkeTrading Posted - 3 months ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Daiichi Sankyo Co Ltd ADR. Is that bullish or bearish? $DSNKY #DSNKY #pink #tradingsignals #technicalanalysis

HemaFL24 Posted - 07/31/24

$DSNKY called it! Above $40 🚀

HemaFL24 Posted - 4 months ago

$DSNKY lets go $40+🚀🚀

Rescueoncredit Posted - 4 months ago

$DSNKY soon they will buy Esperion therapeutics.

JD_Da_Boss Posted - 06/29/24

$DSNKY this very bad stocks just failed! now must to hari kari https://finance.yahoo.com/m/ac27174d-24b9-3065-bb61-b5c58631159a/dow-jones-powerhouse-merck.html

DonCorleone77 Posted - 05/30/24

$CGEN $AZN $DSNKY Compugen to receive $5M milestone payment from AstraZeneca Compugen (CGEN) is entitled to receive a $5M milestone payment from AstraZeneca (AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The trial is evaluating the efficacy and safety of rilvegostomig as monotherapy and in combination with datopotamab deruxtecan, AstraZeneca and Daiichi Sankyo's (DSNKY) TROP2-directed antibody drug conjugate versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo. The ARTEMIDE-Biliary01 Phase 3 trial is evaluating the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in patients with biliary tract cancer after surgical resection with curative intent.

Broview Posted - 6 months ago

$DSNKY low key but with promising oncology portfolio?

DonCorleone77 Posted - 7 months ago

$AZN $DSNKY 2 of 2 - ENHERTU approved for treatment of unresectable or metastatic HER2 positive ....The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02, DESTINY-Lung01 or DESTINY-CRC02. The major efficacy outcome measure in all three of the studies was confirmed ORR and an additional efficacy outcome measure was DOR. ENHERTU is approved with Boxed WARNINGS for interstitial lung disease/pneumonitis and Embryo-Fetal toxicity.

DonCorleone77 Posted - 7 months ago

$AZN $DSNKY 1 of 2 - ENHERTU approved for treatment of unresectable or metastatic HER2 positive Daiichi Sankyo (DSNKY) and AstraZeneca's (AZN) ENHERTU has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ENHERTU is a specifically engineered HER2 directed antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca....

NEWBIGTECH Posted - 8 months ago

$ESPR Maybe call the company , and $DSNKY TO keep everyone in the loop. I am sure they would want to also know why the stock is manipulated, or at least seems to be.

NEWBIGTECH Posted - 8 months ago

$ESPR $DSNKY , I agree, management with ESPR are not doing everything possible to bring the stock price up, or protect the company. I have called and left messages with the company to no avail. That is why I also add the SEC in all correspondence.

NEWBIGTECH Posted - 8 months ago

$ESPR GSA Capital Partners LLP Has $1.09 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) A number of analysts have issued reports on ESPR shares. HC Wainwright cut their price objective on shares of Esperion Therapeutics from $22.00 to $16.00 and set a "buy" rating for the company in a report . $PFE $JNJ #AMGN $DSNKY

YoloAlfred Posted - 9 months ago

$ESPR add $DSNKY to your watchlist

YoloAlfred Posted - 01/31/24

$ESPR I had ticker $DSNKY added this morning. .....put it on your watchlist (our partner in EU)

YoloAlfred Posted - 01/31/24

$DSNKY

YoloAlfred Posted - 01/31/24

$DSNKY OK ESPR CLUB.....add this to your watchlist to follow our partner in Europe